ElectroCore (NASDAQ: ECOR) on Non-Invasive Pain Relief, Federal Channels & 2026 Catalysts

Why It Matters

Electrocore’s rapid growth, federal‑contract foothold, and platform expansion position it to capture a sizable share of the non‑opioid pain‑relief market, offering investors upside as healthcare spending shifts toward device‑based therapies.

Key Takeaways

• Electrocore posted $32M FY2025 revenue, $9.6M total Q1 2026.
• New COO Mike Fox brings 35 years federal sales experience.
• VA accounts represent roughly 80% of 2025 revenue.
• Platform focus on non‑invasive vagal nerve stimulation expanding indications.
• 2026 catalysts: R&D progress, broader federal contracts, operating leverage.

Summary

The interview on the Planet Micro Cap podcast spotlights Electrocore (NASDAQ:ECOR), a bio‑electronic health‑tech firm that develops non‑invasive vagal‑nerve stimulation devices. Interim President and CFO Joshua Lev discusses the company’s recent performance and its upcoming investor conference in Las Vegas.

Electrocore reported $32 million of total revenue for FY 2025 and $9.6 million in Q1 2026, reflecting a compounded annual growth rate above 50 % over five years while trimming cash burn and improving adjusted EBITDA by 24 % year‑over‑year. The VA accounted for roughly $26 million of 2025 sales, underscoring the firm’s reliance on federal contracts.

Lev highlighted the appointment of COO Mike Fox, who brings 35 years of federal‑sales expertise and previously grew a VA‑focused business from $20 million to $80 million in 18 months. He also emphasized that Electrocore’s NVNS platform is moving beyond a single‑product, single‑customer narrative toward multiple indications such as fibromyalgia and chronic pain.

The company’s 2026 catalysts—R&D milestones, expansion into other federal payors (Tricare, Federal Workers’ Comp, Kaiser) and greater operating leverage—could accelerate top‑line growth and improve margins, making ECOR a potentially attractive play for investors seeking exposure to non‑opioid pain‑relief technologies and government‑backed health markets.

Original Description

In this interview, Joshua Lev, Interim-President and CFO of electroCore, Inc. (NASDAQ: ECOR), discusses the company's innovative bio-electronic health products, recent growth, strategic focus on platform technologies, and upcoming catalysts for 2026.

Chapters:

00:00 Introduction to electroCore and Its Mission

04:08 Recent Developments and Leadership Changes

06:45 Future Catalysts and Growth Strategies

electroCore, Inc. will be presenting at the upcoming Planet MicroCap Las Vegas 2026 powered by MicroCapClub. Register to attend here: https://www.meetmax.com/sched/event_130817/conference_home.html

For more information about electroCore, Inc., please visit: https://www.electrocore.com/

The interview may contain forward looking statements about electroCore, Inc. See electroCore, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Planet Microcap hosts the highest quality in-person microcap events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow.; visit https://planetmicrocap.com/ to learn more about our Las Vegas and Toronto events.

This presentation is for informational purposes only and should not be construed as a recommendation to purchase or sell any security referenced herein. Planet MicroCap Holdings LLC and MicroCapClub LLC (collectively, “we” or “our”) are not licensed brokers nor registered investment advisors. We, our partners, contractors, members, subscribers, guests, or affiliates may or may not hold positions in one or more of the securities mentioned in this presentation and may trade in such securities at any time. We may have received cash compensation from one or more participants for presenting at past, present, or future events. We recommend you consult a licensed investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this presentation.